BIO 2005: The global quest for biotech investments

The Chicago Tribune reports from BIO 2005 in Philadelphia on the enormous enthusiasm for biotechnology investments in the U.S. and around the world. An industry that boasts of highly paid, well-educated workers in search of rewarding products has attracted a host of economic development groups that are desperate to woo new biotech businesses their way. Next year the focus will shift from Philadelphia to Chicago, which will host the 2006 annual convention in hopes of raising the profile of the Midwest's biotech industry.

- read this story from the Chicago Tribune for more

ALSO: Ireland used BIO to help tout its position in the global biotech business. Story

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.